Consistency: Have you been dosing daily without significant gaps
Expected timeline: Week 1 to 3: Reduction in inflammation, improved mobility, some pain relief Week 3 to 6: Significant improvement in nerve symptoms, increased functional capacity Week 6 to 12: Continued tissue remodeling, disc structural improvements Month 3 to 6: Full benefits of the protocol become apparent as remodeled tissue matures Understanding proper peptide storage is critical during multi-week protocols
"Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract" Current Pharmaceutical Design, 17(16):1612-1632 "BPC 157 and blood vessels" Current Pharmaceutical Design, 20(7):1121-1125 "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth" Journal of Orthopaedic Research, 21(6):976-983 "Stable gastric pentadecapeptide BPC 157-NO-system relation" Current Pharmaceutical Design, 20(7):1126-1135 "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications" Current Neuropharmacology, 14(8):857-865 This product is a chemical raw material intended exclusively for in vitro research, scientific, and analytical applications
Blocking inflammatory pathways (MAPK and iNOS) restored its levels
